MetaCap

Monte Rosa Therapeutics (GLUE) vs Iambic Therapeutics (IAM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Monte Rosa Therapeutics is the larger company by market cap ($738.3 million vs $621.4 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GLUE-14.62%IAM-30.67%
+30%-10%-50%
Oct 15, 20261 yearNov 20, 2026
GLUE-11.29%IAM-44.94%
+15%-23%-61%
Oct 12, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GLUE versus IAM key metrics
MetricGLUEIAM
Share price$8.64$13.11
Market cap$738.29M$621.42M
1-day change-3.03%-8.06%
YTD return-44.90%—
1-year return-39.24%—
5-year return-57.96%—
EPS (TTM)$-1.39$-2.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$123.67M—
Revenue growth (YoY)+63.54%—
Net income (latest FY)$-38.60M—
Operating margin-43.83%—
Net margin-31.21%—
52-week high$25.77$25.00
52-week low$8.48$9.60
Distance from 52-week high-66.47%-47.56%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+193.75%+107.86%
Average volume1.37M714.92K
Shares outstanding85.45M47.40M
Employees185171
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Monte Rosa Therapeutics

GLUE stock →

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 185 employees

About Iambic Therapeutics

IAM stock →

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 171 employees

GLUE vs IAM FAQ

Which is bigger, Monte Rosa Therapeutics or Iambic Therapeutics?

Monte Rosa Therapeutics (GLUE) is larger, with a market capitalization of $738.29M compared with $621.42M for Iambic Therapeutics (IAM).

Are Monte Rosa Therapeutics and Iambic Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons